A citation-based method for searching scientific literature

Nicole Pfarr, Martina Kirchner, Ulrich Lehmann, Jonas Leichsenring, Sabine Merkelbach-Bruse, Julia Glade, Michael Hummel, Fabian Stögbauer, Annika Lehmann, Marcel Trautmann, Jörg Kumbrink, Andreas Jung, Wolfgang Dietmaier, Volker Endris, Daniel Kazdal, Matthias Evert, David Horst, Hans Kreipe, Thomas Kirchner, Eva Wardelmann, Ulrik Lassen, Reinhard Büttner, Wilko Weichert, Manfred Dietel, Peter Schirmacher, Albrecht Stenzinger. Genes Chromosomes Cancer 2020
Times Cited: 26







List of co-cited articles
165 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
James P Solomon, Irina Linkov, Andrea Rosado, Kerry Mullaney, Ezra Y Rosen, Denise Frosina, Achim A Jungbluth, Ahmet Zehir, Ryma Benayed, Alexander Drilon,[...]. Mod Pathol 2020
124
61

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
C Marchiò, M Scaltriti, M Ladanyi, A J Iafrate, F Bibeau, M Dietel, J F Hechtman, T Troiani, F López-Rios, J-Y Douillard,[...]. Ann Oncol 2019
96
57

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
918
57

Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Jaclyn F Hechtman, Ryma Benayed, David M Hyman, Alexander Drilon, Ahmet Zehir, Denise Frosina, Maria E Arcila, Snjezana Dogan, David S Klimstra, Marc Ladanyi,[...]. Am J Surg Pathol 2017
182
50


NTRK fusion-positive cancers and TRK inhibitor therapy.
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon. Nat Rev Clin Oncol 2018
378
46

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
245
42

Molecular characterization of cancers with NTRK gene fusions.
Zoran Gatalica, Joanne Xiu, Jeffrey Swensen, Semir Vranic. Mod Pathol 2019
169
42

Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics.
Ryosuke Okamura, Amélie Boichard, Shumei Kato, Jason K Sicklick, Lyudmila Bazhenova, Razelle Kurzrock. JCO Precis Oncol 2018
112
38

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.
Ryma Benayed, Michael Offin, Kerry Mullaney, Purvil Sukhadia, Kelly Rios, Patrice Desmeules, Ryan Ptashkin, Helen Won, Jason Chang, Darragh Halpenny,[...]. Clin Cancer Res 2019
123
38

Testing algorithm for identification of patients with TRK fusion cancer.
Frédérique Penault-Llorca, Erin R Rudzinski, Antonia R Sepulveda. J Clin Pathol 2019
60
38


The landscape of kinase fusions in cancer.
Nicolas Stransky, Ethan Cerami, Stefanie Schalm, Joseph L Kim, Christoph Lengauer. Nat Commun 2014
488
30

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types.
Alessio Amatu, Andrea Sartore-Bianchi, Salvatore Siena. ESMO Open 2016
231
30

TRKing down an old oncogene in a new era of targeted therapy.
Aria Vaishnavi, Anh T Le, Robert C Doebele. Cancer Discov 2015
289
30

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
David S Hong, Steven G DuBois, Shivaani Kummar, Anna F Farago, Catherine M Albert, Kristoffer S Rohrberg, Cornelis M van Tilburg, Ramamoorthy Nagasubramanian, Jordan D Berlin, Noah Federman,[...]. Lancet Oncol 2020
149
30

Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma.
B P Rubin, C J Chen, T W Morgan, S Xiao, H E Grier, H P Kozakewich, A R Perez-Atayde, J A Fletcher. Am J Pathol 1998
261
26


Identifying patients with NTRK fusion cancer.
J P Solomon, R Benayed, J F Hechtman, M Ladanyi. Ann Oncol 2019
56
26

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Theodore W Laetsch, Steven G DuBois, Leo Mascarenhas, Brian Turpin, Noah Federman, Catherine M Albert, Ramamoorthy Nagasubramanian, Jessica L Davis, Erin Rudzinski, Angela M Feraco,[...]. Lancet Oncol 2018
209
26

Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
Erin R Rudzinski, Christina M Lockwood, Bradley A Stohr, Sara O Vargas, Rachel Sheridan, Jennifer O Black, Veena Rajaram, Theodore W Laetsch, Jessica L Davis. Am J Surg Pathol 2018
89
23

Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.
Cristina Tognon, Stevan R Knezevich, David Huntsman, Calvin D Roskelley, Natalya Melnyk, Joan A Mathers, Laurence Becker, Fatima Carneiro, Nicol MacPherson, Doug Horsman,[...]. Cancer Cell 2002
537
23

TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations.
Ezra Y Rosen, Debra A Goldman, Jaclyn F Hechtman, Ryma Benayed, Alison M Schram, Emiliano Cocco, Sophie Shifman, Yixiao Gong, Ritika Kundra, James P Solomon,[...]. Clin Cancer Res 2020
28
23

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.
A Vaishnavi, M Capelletti, A T Le, S Kako, M Butaney, D Ercan, S Mahale, K D Davies, D L Aisner, A B Pilling,[...]. Nat Med 2013
352
23

FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors.
Eileen Shi, Juliann Chmielecki, Chih-Min Tang, Kai Wang, Michael C Heinrich, Guhyun Kang, Christopher L Corless, David Hong, Katherine E Fero, James D Murphy,[...]. J Transl Med 2016
97
19

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, Manish Patel, Myung Ju Ahn, Jeeyun Lee, Todd M Bauer, Anna F Farago, Jennifer J Wheler, Stephen V Liu,[...]. Cancer Discov 2017
370
19

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
19

Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.
Thomas Wiesner, Jie He, Roman Yelensky, Rosaura Esteve-Puig, Thomas Botton, Iwei Yeh, Doron Lipson, Geoff Otto, Kristina Brennan, Rajmohan Murali,[...]. Nat Commun 2014
323
19

Anchored multiplex PCR for targeted next-generation sequencing.
Zongli Zheng, Matthew Liebers, Boryana Zhelyazkova, Yi Cao, Divya Panditi, Kerry D Lynch, Juxiang Chen, Hayley E Robinson, Hyo Sup Shim, Juliann Chmielecki,[...]. Nat Med 2014
471
19

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Alexander Drilon, Ramamoorthy Nagasubramanian, James F Blake, Nora Ku, Brian B Tuch, Kevin Ebata, Steve Smith, Veronique Lauriault, Gabrielle R Kolakowski, Barbara J Brandhuber,[...]. Cancer Discov 2017
177
19

TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
Catherine M Albert, Jessica L Davis, Noah Federman, Michela Casanova, Theodore W Laetsch. J Clin Oncol 2019
36
19

Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
Emiliano Cocco, Alison M Schram, Amanda Kulick, Sandra Misale, Helen H Won, Rona Yaeger, Pedram Razavi, Ryan Ptashkin, Jaclyn F Hechtman, Eneda Toska,[...]. Nat Med 2019
59
19

Testing for ROS1 in non-small cell lung cancer: a review with recommendations.
Lukas Bubendorf, Reinhard Büttner, Fouad Al-Dayel, Manfred Dietel, Göran Elmberger, Keith Kerr, Fernando López-Ríos, Antonio Marchetti, Büge Öz, Patrick Pauwels,[...]. Virchows Arch 2016
113
15

Secretory Breast Carcinoma: A Histopathologic and Genomic Spectrum Characterized by a Joint Specific ETV6-NTRK3 Gene Fusion.
Marie Del Castillo, Frédéric Chibon, Laurent Arnould, Sabrina Croce, Agnès Ribeiro, Gaëlle Perot, Isabelle Hostein, Sameh Geha, Catherine Bozon, Agnès Garnier,[...]. Am J Surg Pathol 2015
44
15


The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
Steven G DuBois, Theodore W Laetsch, Noah Federman, Brian K Turpin, Catherine M Albert, Ramamoorthy Nagasubramanian, Megan E Anderson, Jessica L Davis, Hope E Qamoos, Mark E Reynolds,[...]. Cancer 2018
59
15

Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.
Alanna J Church, Monica L Calicchio, Valentina Nardi, Alena Skalova, Andre Pinto, Deborah A Dillon, Carmen R Gomez-Fernandez, Namitha Manoj, Josh D Haimes, Joshua A Stahl,[...]. Mod Pathol 2018
63
15

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
969
15

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
139
15

Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern.
Florian Haller, Jasmin Knopf, Anne Ackermann, Matthias Bieg, Kortine Kleinheinz, Matthias Schlesner, Evgeny A Moskalev, Rainer Will, Ali Abdel Satir, Ibtihalat E Abdelmagid,[...]. J Pathol 2016
67
15

TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.
Shivaani Kummar, Ulrik N Lassen. Target Oncol 2018
39
15

NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
Sarah Chiang, Paolo Cotzia, David M Hyman, Alexander Drilon, William D Tap, Lei Zhang, Jaclyn F Hechtman, Denise Frosina, Achim A Jungbluth, Rajmohan Murali,[...]. Am J Surg Pathol 2018
92
15

NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assays.
Martina Kirchner, Julia Glade, Ulrich Lehmann, Sabine Merkelbach-Bruse, Michael Hummel, Annika Lehmann, Marcel Trautmann, Jörg Kumbrink, Andreas Jung, Wolfgang Dietmaier,[...]. Genes Chromosomes Cancer 2020
8
50

NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases.
Angela Chou, Tamara Fraser, Mahsa Ahadi, Talia Fuchs, Loretta Sioson, Adele Clarkson, Amy Sheen, Nisha Singh, Christopher L Corless, Anthony J Gill. Mod Pathol 2020
19
21

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.
Esther Conde, Susana Hernandez, Rebeca Martinez, Barbara Angulo, Javier De Castro, Ana Collazo-Lorduy, Beatriz Jimenez, Alfonso Muriel, Jose Luis Mate, Teresa Moran,[...]. J Thorac Oncol 2019
27
15

Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.
Lawrence J Jennings, Maria E Arcila, Christopher Corless, Suzanne Kamel-Reid, Ira M Lubin, John Pfeifer, Robyn L Temple-Smolkin, Karl V Voelkerding, Marina N Nikiforova. J Mol Diagn 2017
241
15


RET, ROS1 and ALK fusions in lung cancer.
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Ritsuro Suzuki, Seiji Sakata, Satoko Hatano, Reimi Asaka, Wakako Hamanaka, Hironori Ninomiya, Hirofumi Uehara,[...]. Nat Med 2012
834
11


Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma.
Justin A Bishop, Raluca Yonescu, Denise Batista, Shahnaz Begum, David W Eisele, William H Westra. Hum Pathol 2013
99
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.